Filters
Price
Category
Peptides
Administration
Dosage
Research Focus
Brand
Rating
Status
Best Sellers
-
DSIP
Rated 5.00 out of 5£34.99Original price was: £34.99.£31.99Current price is: £31.99.mg -
GHK-Cu (Pen)
£74.99 – £94.99Price range: £74.99 through £94.99
-
SLU-PP-332
£79.99
-
GHRP-6
£19.99Original price was: £19.99.£17.99Current price is: £17.99.mg -
AOD 9604
£39.99 – £69.99Price range: £39.99 through £69.99mg
Showing 1–12 of 13 results
Showing 1–12 of 13 results
AOD 9604
£39.99 – £69.99Price range: £39.99 through £69.99mgAOD-9604
AOD-9604 is a modified C-terminal fragment of human growth hormone developed to isolate lipolytic properties without stimulating IGF-1 or producing the anabolic side effects of full-length GH. Received GRAS status from the FDA as a food additive ingredient.
BPC-157
£64.99mgGHK-Cu (Pen)
£74.99 – £94.99Price range: £74.99 through £94.99GHK-Cu
Gly-His-Lys · Cu²⁺
GHK-Cu is a naturally occurring copper peptide first isolated from human plasma in 1973. It upregulates over 4,000 human genes, stimulates collagen synthesis, exerts antioxidant effects, and demonstrates broad anti-inflammatory activity. A well-established topical cosmetic ingredient with growing interest in systemic applications.
Retatrutide (Pen)
£54.99 – £124.99Price range: £54.99 through £124.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks










